Thromb Haemost 1970; 24(03/04): 352-355
DOI: 10.1055/s-0038-1654244
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Protection from Hg-Inactivation of Factor XIII by Mercaptalbumin

P Fantl*
1   Baker Medical Research Institute Melbourne, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Summary

The blood plasma factor XIII (fibrin stabilizing factor) is inactivated by mercuric ions and can be reactivated by serum - or plasma albumin of which the active component is mercaptalbumin. A relation between mercaptalbumin concentration and factor XIII activity is pointed out.

* Postal Address: Baker Medical Research Institute, Commercial Road, Prahran, Victoria 3181, Australia.


 
  • References

  • 1 Coopland A, Allcjaersig N, Fletcher A. P. Reduction in plasma factor XIII (fibrin stabilizing factor) concentration during pregnancy. J. Lab. clin. Med 73: 144 1969;
  • 2 Coryell M. N, Beach E. F, Robinson A. R, Macy I. G, Mack H. G. Metabolism of women during the reproductive cycle. XVII. Changes in electrophoretic patterns of plasma proteins throughout the cycle and following delivery. J. clin. Invest 29: 1559 1950;
  • 3 Davisson E. O, Powell H. M, MacFarlane F. O, Hodgson R, Stone R. L, Culbertson C. G. The preservation of poliomyelitis vaccine with stabilized merthiolate. J. Lab. clin. Med 47: 8 1956;
  • 4 Fanti P, Ward H. A. Molecular weight of human fibrinogen derived from phosphorus determinations. Biochem. J 96: 886 1965;
  • 4a Fanti P. Thiol distribution and Mercaptalbumin reactivity in the blood plasma of different vertebrates. Aust. J. exp. Biol. med. Sci. (In press.)
  • 5 Geraldes J. N. Proportion of activity of the stabilizing factor of fibrin (factor XIII) during labour and puerperium. Rev. clin. Inst. Matern 18: 183 1969;
  • 6 Kunzer W. T, Lutgemeier J. Zur entwicklungsbedingten Abhängigkeit des Plasmagehaltes an fibrinstabilisierendem Faktor (FSF). Ann. Paediat 204: 232 1965;
  • 7 Laki K, Lorand L. On the solubility of fibrin clots. Science 108: 280 1948;
  • 8 Loewy A. G. In: Fibrinogen. Ed. Laki K. Dekker N. Y: 1968
  • 8a Moore D. H, Martin R, du Pan Buxton C. L. An electrophoretic study of maternal, fetal and infant sera. Amer. J. Obstet 51: 312 1949;
  • 9 Nussbaum M, Morse B. S. Plasma fibrin stabilizing factor activity in various diseases. Blood 23: 669 1964;
  • 10 Ottaviani P, Mandelli F, Fontana L, Morelli R. Comportomento del fattore stabilizzante fibrinico nelli epato patie. Prog. Med 21: 115 1965;
  • 11 Roberts E, Rouser G. Spectrophotometric assay for reaction of N-ethylmaleiimide with sulphydrylgroups. Analyt. Chem 30: 1291 1958;
  • 12 Swigert S, Koppel J. L, Olwin J. H. Selective inactivation of fibrin stabilizing factor contaminant in fibrinogen. Nature (Lond) 198: 797 1963;
  • 13 Walls W. D, Losowsky M. S. Plasma fibrin stabilizing factor (FSF) activity in normal subjects and patients with chronic liver disease. Thrombos. Diathes. haemorrh. (Stuttg) 21: 134 1969;